Navigation Links
LSUHSC research yields promising stroke treatment
Date:1/23/2010

New Orleans, LA For the first time, research led by Youming Lu, PhD, MD, Professor of Neurology and Neuroscience at LSU Health Sciences Center New Orleans School of Medicine, has identified a novel mechanism that may trigger brain damage during stroke and identified a therapeutic approach to block it. The work, funded by the National Institute on Aging (NIA) and the National Institute of Neurological Disorders and Stroke (NINDS), both of the National Institutes of Health (NIH), as well as the American Heart Association, will be published in the January 22, 2010 issue of the top tier journal, Cell, available online at 12:00 noon ET on January 21, 2010.

The work focuses on particular receptors for the neurotransmitter, glutamate, called NMDA (N-methyl-D-aspartate) receptors, which constitute the major subtype of glutamate receptors. NMDA receptors play a key role in communication among nerve cells in the brain. They perform a number of necessary functions including playing a role in learning and memory, but can also be involved in processes that cause brain cell death. Under normal conditions, signaling through NMDA receptors prevents the deleterious overload of cells with calcium, but during insults like stroke, this process is disabled. Calcium overload triggers multiple intracellular processes which result in irreversible death of brain cells. The research team discovered that an enzyme, DAPK1 (Death-Associated Protein Kinase 1), binds to a portion of the NMDA receptor, and acts as a specific "NMDA receptor cell death signal" during stroke. The researchers wanted to determine whether the process could be circumvented by disrupting the DAPK1-NMDA receptor binding, and they developed a high potency reagent to test. The reagent not only blocked DAPK1, protecting brain cells against stroke insults, but it did so without affecting other physiological functions of NMDA receptors.

To date, all stroke clinical trials targeting glutamate receptors have failed, largely because of their side effects, inefficient delivery through the blood-brain barrier, and/or a limited time window for therapeutic intervention.

"It is conceivable that this study not only provides new insights into the cellular and molecular basis responsible for stroke damage, but also provides a therapeutic target for stroke therapy," says Dr. Youming Lu, who is also a research scientist at the LSU Health Sciences Center New Orleans Neuroscience Center of Excellence.

According to the American Heart Association, stroke is the third leading cause of death in the United States and is a leading cause of serious, long-term disability. NIH-supported research suggests that about one in six Americans will experience a stroke at some point after age 65 and stroke is fatal in 10-20% of cases. Louisiana is in the "stroke belt," an eight-state region in the southeastern United States which one recent study found had a more than 40% higher stroke mortality rate than the rest of the nation.

"By determining that the interaction between the NMDA receptor NR2B subunit and DAPK1 kinase serves as a trigger for cell death during stroke, this research points to a new therapeutic approach for the treatment of stroke that may avoid the negative side effects that have plagued the development of stroke therapeutics to date." said Dr. Suzana Petanceska, of the NIA Division of Neuroscience. "Furthermore, the therapeutic significance of these findings may reach beyond stroke to other neurodegenerative diseases of aging."


'/>"/>

Contact: Leslie Capo
lcapo@lsuhsc.edu
504-568-4806
Louisiana State University Health Sciences Center
Source:Eurekalert

Related medicine news :

1. LSUHSC dental school to be awarded top national honor
2. LSUHSC inventor awarded patent for new procedure to detect cancer spread
3. LSUHSC study finds high-dose HBO2 therapy extends survival window after cardiopulmonary arrest
4. LSUHSC awarded grant to address nursing shortage
5. LSUHSC public health contributes to estimate of HPV-related cancers
6. LSUHSCs Fontham makes history
7. LSUHSCs Dr. Xiao Cheng Wu co-authors annual report to the nation on cancer
8. LSUHSCs England leads development of new testing guidelines for common nerve disorder
9. LSUHSC research may benefit diabetes by increasing understanding of how to control islet cell growth
10. LSUHSC research shows fish oil protects against diseases like Parkinsons
11. LSUHSC dental researcher funded to develop better dental materials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... 23, 2017 , ... Natural Subsistence, a company known for ... and nutrition, announced its product Leyzene is now available for purchase on Go4ItNutrition.com, ... that help people improve all aspects of their health so they can live ...
(Date:3/23/2017)... ... March 23, 2017 , ... The American Board of ... the 40th Anniversary of ABQAURP’s dedication to Health Care Quality and Management and Patient ... contributed not only to the association, but also to the Health Care Quality and ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... with European Guidelines and the New MEDDEV 2.7/1 Rev. 4 Guidance, **An ... http://www.fdanews.com/mdclineval                  , How will the new EU MDR language change ...
(Date:3/23/2017)... ... March 23, 2017 , ... “Beyond and Back”: a true-life testimony of tragedy ... of published author Bonetta Rose, a wife, mother and grandmother committed to sharing her ... Faith Publishing, Bonetta Rose‘s new book presents actual events in the life of her ...
(Date:3/23/2017)... ... March 23, 2017 , ... “A Respectful ... “A Respectful Response To Atheist Manifesto” is the creation of published author Richard ... Nancy, for sixty years. He holds graduate degrees from Kent State University and ...
Breaking Medicine News(10 mins):
(Date:3/22/2017)... de marzo de 2017   VWR ... soluciones de productos y servicios para clientes de ... adquirido EPL Archives, Inc., una organización de servicios ... todo el ciclo de vida de investigación de ... de archivo, almacenamiento de documentos y servicios complementarios. ...
(Date:3/22/2017)... 22, 2017 Ampio Pharmaceuticals, Inc. (NYSE ... Ampion™, a low molecular weight fraction of human ... it is re-issuing its previous release that was made ... that are required under the NYSE MKT Company ... additional disclosures along with the previously disclosed update ...
(Date:3/22/2017)... New Jersey,s hospitals ... and saved $641 million in healthcare costs between 2012 ... quality improvement program. The results reflect ... part of a national initiative from the U.S. Department ... Jersey Hospital Association and its affiliate, the Health Research ...
Breaking Medicine Technology: